13th International Congress
13th International Congress

News Release

Monday, June 8, 2009

Media Contact:
Elizabeth Laur, elaur@movementdisorders.org
+1 414-276-2145 (MDS Secretariat)
MDS 13th International Congress Press Room (June 7-11):
Le Palais des Congres de Paris,
Room 212/213, Level 2, Hall Maillot, TEL: +33 (0)1 40 68 63 74

Gene Therapy Represents a Future Treatment Strategy for Parkinson's Disease

PARIS - A study investigating the effects of AAV-AADC gene therapy to evaluate the safety and tolerability in patients with moderately severe Parkinson's disease was presented at The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders.

In this phase I clinical trial, 10 patients with advanced Parkinson's disease received two different doses of gene therapy with human aromatic L-amino acid decarboxylase (ADCC) using adeno associated viral vector and intraputaminal delivery. The study was conducted by Michael J. Aminoff, MD, DSc, and a team of other scientists from the University of California, San Francisco.

Andres Lozano, MD, University of Toronto, states "In this open labeled study, there were improvements in the total and motor UPDRS and encouragingly, also increases in fluoro meta-tyrosine, an ADCC tracer. There were however 3 patients (30%) who experienced an intracranial hemorrhage albeit only 1 producing overt symptoms. This is important and promising work that deserves to be validated in a double blind placebo controlled trial. In addition, efforts should be made to understand the high incidence of intracerebral hemorrhage and to reduce its occurrence."

Meeting attendees are gathered to learn the latest research findings and state-of-the-art treatment options for Movement Disorders, including Parkinson's disease. More than 3,900 physicians and medical professionals from 90 countries will be able to view over 1,700 scientific abstracts submitted by clinicians from around the world.

The Movement Disorder Society, an international society of over 3,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research.

For more information about The Movement Disorder Society, visit www.movementdisorders.org